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Characterizing the type 2 diabetes 
mellitus epidemic in Jordan 
up to 2050
Susanne F. Awad1,2,3*, Peijue Huangfu4, Soha R. Dargham1,2, Kamel Ajlouni5, 
Anwar Batieha6, Yousef S. Khader6, Julia A. Critchley4 & Laith J. Abu‑Raddad1,2,3*
We aimed to characterize the type 2 diabetes mellitus (T2DM) epidemic and the role of key risk 
factors in Jordan between 1990–2050, and to forecast the T2DM‑related costs. A recently‑developed 
population‑level T2DM mathematical model was adapted and applied to Jordan. The model was 
fitted to six population‑based survey data collected between 1990 and 2017. T2DM prevalence was 
14.0% in 1990, and projected to be 16.0% in 2020, and 20.6% in 2050. The total predicted number of 
T2DM cases were 218,326 (12,313 were new cases) in 1990, 702,326 (36,941 were new cases) in 2020, 
and 1.9 million (79,419 were new cases) in 2050. Out of Jordan’s total health expenditure, 19.0% in 
1990, 21.1% in 2020, and 25.2% in 2050 was forecasted to be spent on T2DM. The proportion of T2DM 
incident cases attributed to obesity was 55.6% in 1990, 59.5% in 2020, and 62.6% in 2050. Meanwhile, 
the combined contribution of smoking and physical inactivity hovered around 5% between 1990 
and 2050. Jordan’s T2DM epidemic is predicted to grow sizably in the next three decades, driven by 
population ageing and high and increasing obesity levels. The national strategy to prevent T2DM 
needs to be strengthened by focusing it on preventive interventions targeting T2DM and key risk 
factors.
The diabetes mellitus (DM) epidemic is a global public health concern and the seventh leading cause of death 
 worldwide1. Besides demographic  determinants2, it is established that the underlying epidemiology of the type 2 
DM (T2DM) epidemic, which contributes greater than 90% of all DM  cases2, is strongly influenced by modifiable 
risk factors such as obesity (defined as body mass index ≥ 30 kg/m2)3–5,  smoking6,7, and physical  inactivity8,9.
The Middle East and North Africa (MENA) region has the second highest DM prevalence worldwide, with 
54.8 million adults (prevalence of 12.8%) estimated to be living with  DM2. This number is projected to reach 107.6 
million by 2045, an increase of 96%2. In Jordan, a MENA country and the focus of our study, several national 
population-based epidemiological surveys, conducted between 1994 and 2017, reported high but variable DM 
prevalence ranging between 9 and 30%10–15. Some also reported high and increasing prevalence of T2DM-related 
risk factors including  obesity10–15,  smoking10–15, and physical  inactivity15.
Against this background, we aimed to project the temporal trends in prevalence and incidence of T2DM 
in Jordan up to 2050, factoring the interplay between T2DM natural history, T2DM-related risk factors, and 
demography. We further aimed to estimate the national heath expenditure directly attributed to T2DM, and to 
delineate the role of the modifiable risk factors of obesity, smoking, and physical inactivity in driving T2DM 
incidence and prevalence.
A highlight of this study is that it applied a recently-developed analytical approach to investigate T2DM epi-
demiology and its  projections16. In contrast to earlier  approaches17–24, this methodology captures the dynamic 
interactions between T2DM and its risk factors. Another highlight is that this study factored and synthesized 
the totality of existing evidence on T2DM and risk factors in Jordan to generate the different estimates—a total 
of six surveys for T2DM and its risk factors were used to calibrate the model.
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Methods
An age-structured T2DM mathematical model was developed to describe the natural history and progression 
of T2DM in the population of Jordan—as an adaptation of a published T2DM modelling  approach16. Briefly, the 
natural history of T2DM was described by the general progression states of (1) four main susceptible classes: 
healthy (i.e. having none of the included T2DM-related risk factors), obese, smoker, and physically inactive; and 
(2) T2DM (including also all risk factor states). The susceptible and T2DM populations were further stratified to 
account for the overlaps between risk factors. The model disaggregated the population by sex and age to accom-
modate for the full demographic transition in the population. Accordingly, a total of 640 coupled differential 
equations were needed to describe T2DM epidemiology in this population. Further details on model structure 
and assumptions can be found in Awad et al.16 and in Supplementary Information Text S1.
Data sources and model fitting. The parameters of the model were based on epidemiological and natural 
history data listed in Tables S2 and S3, and by fitting the model to existing prevalence and demographic meas-
ures.
The model was fitted to different survey data using a least-square fitting  method25. This technique, imple-
mented in MATLAB through the function  FMINSEARCHBND25, minimizes the error function (i.e., cost func-
tion) between all data points and the model predictions starting from an initial set of parameter values, using 
the Nelder–Mead simplex algorithm as described in Lagarias et al.26 The Nelder–Mead algorithm is a commonly 
applied numerical method used to find the minimum of a function in a multidimensional space using the simplex 
 method26,27. In our study, the sum of squared error was used as the cost function to provide a metric representing 
the difference between the data and the model’s predictions for any given set of model parameters. For termina-
tion of the fitting process (and to assess goodness of fit) the tolerance of the error function was set at  10−4.
The model was fitted to sex- and age-specific DM (by assuming all DM cases are due to T2DM), obesity, 
smoking, and physical inactivity prevalence data, as obtained from nationally-representative population-based 
surveys from Jordan conducted in  199412,  200410,  200711,  200914, and  201715, and one community-based survey 
conducted in  200413. Thus, the model was fitted to point estimates (but not confidence intervals) of a total of 323 
prevalence measures. A brief description of the surveys is in Table 1. The data reflects the resident population of 
Jordan, but Syrian refugees were not included in the surveys apart from (partially) in the last 2017  survey15. Due 
to substantial differences in response rate across and within surveys, data were weighted during model fitting 
by survey response rate, and for men and women separately (Table 1). All data used in this study are aggregate, 
de-identified, and anonymized.
The model was also fitted to Jordan’s age-specific and total population size (including 4,242 demographic 
measures) as obtained from the database of the Population Division of the United Nations Department of 
Table 1.  Characteristics of the Jordan population-based surveys used in the analysis for type 2 diabetes 
mellitus (T2DM) and its risk factors.
Survey/study title Survey year Coverage of data Age group
Gender 
distribution Response rate Method of diagnosis for 
diabetes
Risk factors 
reported ReferencesMen Women Men (%) Women (%)
Diabetes and 
impaired glucose 
tolerance in Jordan: 
prevalence and asso-
ciated risk factors
1994 National 25+ 1046 1790 54 86
Fasting blood 
glucose greater than 
126 mg/dl
Obesity
Smoking
12
An increase in 
prevalence of diabe-
tes mellitus in Jordan 
over 10 years
2004 Sarih in Jordan 25+ 394 727 94 94
Either participant 
had previously 
been diagnosed 
with diabetes or 
had a fasting blood 
glucose greater than 
126 mg/dl
Obesity
Smoking
13
STEPwise approach 
to chronic disease 
risk factor surveil-
lance in 2004
2004 National 18+ 1342 1992 85 85
Fasting blood 
glucose greater than 
126 mg/dl
Obesity
Smoking
10
STEPwise approach 
to chronic disease 
risk factor surveil-
lance in 2007
2007 National 18+ 1939 1715 86 86
Fasting blood 
glucose greater than 
126 mg/dl
Obesity
Smoking
11
Relationship 
between 25-hydrox-
yvitamin D and 
metabolic syndrome 
among Jordanian 
adults
2009 12 governorates of Jordan 7+ 776 2458 36 90
Fasting blood 
glucose greater than 
126 mg/dl
Obesity
Smoking
14
Time trends in 
diabetes mellitus in 
Jordan between 1994 
and 2017
2017 National 18+ 1099 2495 40 94
Fasting blood 
glucose greater than 
126 mg/dl
Obesity
Smoking
Physical inactivity
15
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Economic and Social Affairs (Supplementary Fig. S1)28. Due to limited census data for Jordan, we opted to use the 
United Nations Department of Economic and Social Affairs’ estimates as they provide a more complete picture 
of the demography and its evolution using a standardized method that is applied  globally28.
The model was initiated in 1950. The initial conditions for the demographic structure were obtained from 
the database of the Population Division of the United Nations Department of Economic and Social  Affairs28. 
Prevalence of T2DM and related risk factors at initial year were estimated through the fitting process. By gener-
ating the best fit, we quantified the following seven rates: sex- and age-specific T2DM baseline incidence rates 
(i.e. incidences rates from “healthy” to T2DM), and sex- and age-specific transition rates from healthy to obese, 
obese to healthy, healthy to smoker, smoker to healthy, healthy to physically inactive, and physically inactive to 
healthy (Table S2).
Estimating the trends of T2DM and risk factors. Trends in T2DM prevalence and incidence between 
1990 and 2050 in the 20–79 years old population of Jordan were generated using the best fit parameters. Trends 
in risk factors and their effect on T2DM were also predicted for the studied period. The age-specific rates of obe-
sity were allowed to increase between 1990 and 2050 (details in Supplementary Information Text S1), to fit the 
actual trend  data10–15. Meanwhile, the age-specific rates of smoking were assumed to remain constant through-
out, as suggested by the actual trend  data10–15. The age-specific rates of physical inactivity were also assumed to 
remain constant throughout, as only one survey was available for physical  inactivity15, and hence no trend could 
be determined. Accordingly, the predicted temporal changes in smoking and physical inactivity prevalence were 
driven solely by the demographic structure of the population.
The total number of T2DM incident cases attributed to each risk factor was calculated using a methodology 
developed for estimating the population attributable fraction of risk factors, factoring all of their  overlaps16,29,30.
Projections of health expenditure for T2DM. T2DM health expenditure in Jordan was calculated 
using the Jönsson  approach31. This approach estimates the health expenditure that is directly attributed to T2DM 
from the total healthcare expenditure, by converting the per capita health expenditure to estimates of T2DM 
attributable spending. The key parameter for this conversion is the relative ratio of all healthcare expenditure of 
T2DM individuals compared to non-T2DM individuals ( Ras).
As informed by  evidence32, we applied two ratios for Ras (2 and 3) to bracket the range of estimates. We also 
applied two scenarios for the evolution of Jordan’s annual per capita health expenditure over time. First, the 
annual per capita health expenditure was assumed to change between 1990 and 2015, based on historical trend, 
as reported by World Bank data (Supplementary Fig. S4)33, but assumed constant between 2016 and 2050 at the 
2015 level ($257 United States  dollars33). Second, the annual per capita health expenditure was assumed to change 
with time between 1990 and 2050, based on historical trend, as reported by World Bank  data33, but then also 
extrapolated into the future based on this trend (Supplementary Fig. S2)33. No discounting was applied for cost.
Sensitivity and uncertainty analyses. We conducted univariate sensitivity analyses to assess robustness 
of model predictions to variations in the relative risks (RRs) of each risk factor for T2DM incidence, and RR of 
mortality among people with T2DM compared to the general population. Multivariable uncertainty analyses 
were also conducted to specify the ranges of uncertainty in projected T2DM prevalence estimates. The first 
uncertainty analysis was conducted with respect to variations in the key structural model parameters including 
RR of mortality and RR of developing T2DM if obese, smoker, and physically inactive. The second uncertainty 
analysis was conducted with respect to variations in each data point of each survey.
For the first uncertainty analysis, Monte Carlo sampling from log-normal distributions was used for the 
confidence intervals of the epidemiological input parameters (Table S2). Each set of new parameters, generated 
from the specified ranges, was used to refit the model. Through 1,000 uncertainty runs of the model, the likeli-
hood distribution and the 95% uncertainty interval (UI) for T2DM prevalence were estimated.
For the second uncertainty analysis, Monte Carlo sampling from uniform distributions was used assuming 
± 40% uncertainty around each survey data point. Each set of new input data, generated from the specified ranges, 
was used to refit the model. Through 1000 uncertainty runs of the model, the likelihood distribution and the 
95% UI for T2DM prevalence were also estimated.
Finally, we used the regularization  technique34,35 to investigate whether the model and the fitting method 
used in this study could be overfitting the existing data. Briefly, by applying this technique additional terms for 
the fitting parameters were included in the least-square fitting to prevent the fitting parameters from erroneously 
attaining extreme  values34,35.
Results
Supplementary Fig. S1 shows the best-fit of the model to the size of the total population in Jordan as well as to 
the age-specific demographic distribution. Overall, the model produced good fits for the data, but it did not 
capture the transient changes in demography due to sudden influx of refugees and immigrants from the year 
2010 onwards.
Supplementary Fig. S3 shows the best-fit of the model to the data of the sex- and age-specific T2DM preva-
lence surveys that were conducted in 1994, 2004, 2009, and 2017, and also to the data of the T2DM STEPwise 
surveys in 2004 and  200710–15. The best-fit of the model to the various sex- and age-specific prevalence data for 
obesity, smoking, and physical inactivity are shown in Supplementary Figs. S4-S6. Overall, the model produced 
good fits for the data, however, for some individual prevalence measures, the model overestimated or underes-
timated them (Supplementary Figs. S4-S6). These differences may be explained by wider confidence intervals 
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in some of the survey data, or potential biases in the survey measures. For example, in men, non-response rates 
were very high (Table 1)10–15, which may have affected the goodness of fit for some of the measures.
T2DM prevalence and incidence. T2DM prevalence was predicted to increase from 14.0% (95% UI: 
13.0–15.0%) in 1990, to 16.0% (95% UI: 14.8–17.0%) in 2020, and to 20.6% (95% UI: 19.2–21.8%) in 2050. 
T2DM prevalence increased among men from 16.3% in 1990 to 23.1% in 2050, and among women, from 11.5% 
in 1990 to 18.0% in 2050 (Fig. 1A).
The model projected a steady increase in T2DM incidence (Fig. 1C). In 1990, a total of 218,326 people 
were living with T2DM (Fig. 1B), of which 12,313 were new cases (Fig. 1C). Incidence rate was predicted to 
be 4.6 per 1000 person-year (Fig. 1D). In 2020, the total number of T2DM cases were predicted to increase to 
702,326 (Fig. 1B), of which 36,941 would be new cases (Fig. 1C). Incidence rate was predicted to be 5.6 per 
1000 person-year (Fig. 1D). In 2050, the total number of T2DM cases were predicted to increase further to 1.9 
million (Fig. 1B), of which 79,419 would be new cases (Fig. 1C). Incidence rate was predicted to be 6.5 per 1000 
person-year (Fig. 1D).
Health expenditure for T2DM. Figure 2 shows the past, present, and future projected health expenditure 
for T2DM for Ras = 2 and Ras = 3 . In 1990, $50.3–$89.2 were spent per T2DM case resulting in a total expendi-
ture of $11.1–$19.5 million. In this year, T2DM consumed 10.7–19.0% of Jordan’s national health expenditure 
(Fig. 2C).
Assuming fixed annual per capita health expenditure post-2015, $255.4–$439.7 would be spent per T2DM 
case in 2050 resulting in a total expenditure of $487.6–$839.5 million. In this year, T2DM would consume 
14.6–25.2% of national health expenditure (Fig. 2C).
Assuming increasing annual per capita health expenditure per extrapolated historical trend, $486.7–$838.0 
would be spent per T2DM case in 2050 resulting in a total expenditure of $0.9–$1.6 billion. In this year, T2DM 
would consume 14.6–25.2% of national health expenditure (Fig. 2C).
Projections of T2DM‑related risk factors. In the 20–79 years old population, prevalence of obesity was 
predicted to increase from 35.1% in 1990, to 38.0% in 2020, and to 41.4% in 2050 (Supplementary Fig. S8A), 
while smoking slightly decreased from 27.5% in 1990, to 27.2% in 2020, and to 25.9% in 2050 (Supplementary 
Fig. S8B). Prevalence of physical inactivity increased from 16.9% in 1990, to 18.2% in 2020, and to 21.2% in 2050 
(Supplementary Fig.S8C). The changes in smoking and physical inactivity were only driven by the changes in 
the demographic structure of the population—the age-specific prevalence of smoking was assumed constant as 
suggested by trend  data10–15, while the age-specific prevalence of physical inactivity was assumed constant (as a 
neutral assumption) due to limited data to inform the  trend15.
Women had higher obesity prevalence (42.4% in 1990 and 50.9% in 2050) than men (28.3% in 1990 and 
33.6% in 2050; Supplementary Fig. S8A). However, women had lower smoking prevalence (9.9% in 1990 and 
10.5% in 2050) than men (43.9% in 1990 and 40.5% in 2050; Supplementary Fig. S8B). Women had also lower 
Figure 1.  Projected type 2 diabetes mellitus (T2DM) epidemic in Jordan between 1990–2050 in those 
20–79 years old. (A) Prevalence of T2DM. (B) Total number of people living with T2DM. (C) Annual number 
of new T2DM cases. (D) T2DM incidence rate.
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physical inactivity prevalence (13.3% in 1990 and 17.2% in 2050) than men (20.2% in 1990 and 25.0% in 2050; 
Supplementary Fig. S8C).
Proportion of T2DM cases attributable to obesity, smoking, and physical inactivity. Figure 3 
shows the predictions for the proportions of incident T2DM cases that are attributed to each of obesity, smok-
ing, and physical inactivity at four different time points between 1990 and 2050. The proportion of annual 
new T2DM cases attributed to obesity increased from 55.6% in 1990, to 59.5% in 2020, and to 62.6% in 2050 
(Fig. 3A). This proportion increased among men from 45.2% in 1990 to 52.1% in 2050, and among women, from 
72.5% in 1990 to 76.9% in 2050 (Fig. 3A).
The proportion of incident T2DM cases attributed to smoking was constant at 3.2% between 1990 and 2020, 
but decreased slightly to 3.0% in 2050 (Fig. 3B). This proportion decreased among men from 5.3% in 1990 to 
5.2% in 2050, but was constant among women at 0.5% between 1990 and 2050 (Fig. 3B).
The proportion of incident T2DM cases attributed to physical inactivity increased from 2.1% in 1990, to 
2.3% in 2020, and to 2.5% in 2050 (Fig. 3C). This proportion increased among men from 2.7% in 1990 to 3.3% 
in 2050, and among women, from 1.3% in 1990 to 1.4% in 2050 (Fig. 3C).
Sensitivity and uncertainty analyses. The robustness of the findings was assessed in sensitivity analyses 
(Supplementary Fig.S7). In 2050, T2DM prevalence in the 20–79 years old population ranged from 18.4–23.2%, 
20.4–20.8%, and was largely unaltered at 20.6% by varying each RR of developing T2DM if obese, smoker, and 
Figure 2.  Projected health expenditure for type 2 diabetes mellitus (T2DM) in Jordan, 1990–2050. The 
figure shows (A) expenditure assuming fixed annual per capita health expenditure between 2016 and 2050, 
(B) expenditure assuming increasing annual per capita health expenditure between 2016 and 2050 based on 
extrapolation of the increasing historical trend, and (C) proportion of Jordan’s total health expenditure that is 
spent on T2DM. The health expenditure directly attributed to T2DM out of Jordan’s total healthcare expenditure 
was calculated per the Jönsson’s  approach31. The annual per capita health expenditure in Jordan between 1995 
and 2015 was provided by World Bank  data33.
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physically inactive, respectively. T2DM prevalence ranged from 20.0 to 21.4% by varying the RR of mortality in 
T2DM compared to the general population.
The range of uncertainty in the projected T2DM prevalence estimates was assessed in two uncertainty analyses 
(Supplementary Fig.S9A and S9B). The UIs around the trends in T2DM prevalence between 1990 and 2050 were 
relatively narrow highlighting that the predictions were consistent to a wide range of parameter assumptions 
and input data errors or variations.
Finally, the robustness of the findings was also investigated using the regularization  technique34,35 (Supple-
mentary Fig.S9C). Though T2DM prevalence was slightly higher after regularization, it was within the reported 
UIs of the uncertainty analyses (Supplementary Fig. S9A and S9B). Moreover, the trend in T2DM prevalence was 
invariable highlighting the reliability and robustness of our predictions (Supplementary Fig.S9C).
Discussion
We provided a characterization of the T2DM epidemic in Jordan. T2DM prevalence increased by 14.3% between 
1990 and 2020 and was projected to increase further by 28.8% between 2020 and 2050. In 2020, as much as $350 
million would be spent on T2DM, consuming 21% of the national health expenditure. By 2050, T2DM could 
consume about 25% of the national health expenditure. The epidemic was found to be largely driven by obesity, 
contributing about 60% of T2DM incidence. The role of obesity was also more pronounced for women than 
men, reflecting the high prevalence in women that is consistent and observed in the  region36. While smoking and 
physical inactivity played a role in the expanding epidemic, their contribution was small compared to obesity—
both combined contributed only about 5% of T2DM incidence. These findings demonstrate that the epidemic is 
largely a reflection of modifiable risk factors, namely obesity, and is best addressed through appropriate lifestyle 
interventions that improve the health profile of the population.
Figure 3.  Projections for the proportion of annual new type 2 diabetes mellitus (T2DM) cases in Jordan that is 
attributed to each key T2DM-related risk factor, 1990–2050. The figure shows projected proportions of T2DM 
cases attributed to (A) obesity, (B) smoking, and (C) physical inactivity.
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Demography was found to play a major role in the epidemic expansion over the next three decades. The 
population of Jordan was projected to grow by 89% between 2020 and 2050, while the mean age of the population 
would increase by seven years, from 26 to 33 years. The coupling of increasing population size with progressive 
aging demonstrates how difficult it will be to halt or control the epidemic. The number of people living with 
T2DM was projected to rapidly increase from 218,326 in 1990, to 702,326 in 2020 and 1.9 million in 2050, swiftly 
straining an already resource-strained healthcare system. Jordan is all but destined to confront an immense 
healthcare challenge and an escalating health expenditure that it may not be able to afford.
Evidence indicates that policy-level facilitation is essential to yield an environment that nudges people to 
make the right choices to reduce their lifestyle risk factors, and thus T2DM  risk37–39. Studies have shown that 
structural interventions targeting T2DM or its risk factors have the potential to change T2DM epidemiology 
and impact the  epidemic37,38,40. Such structural interventions are often fiscal, legislative, or environmental in 
nature, and outside the immediate control of the individual or the health sector. They include policies to reduce 
consumption of unhealthy foodstuffs through fiscal regulations (e.g. increasing taxation on sugar-sweetened 
beverages), or subsidies for healthier foods (e.g. fruits and vegetables)40. However, the feasibility and political 
palatability of such approaches in Jordan require further consideration and investigation.
Other studies have projected the burden of T2DM in Jordan. The International Diabetes Federation (IDF)41 
estimated that T2DM prevalence for those aged 20–79 was 9.5% in 2017 and will increase to 12.5% in 2045—an 
increase of 31.6%41. Though the prevalence of T2DM was projected to be higher in our study, the projected 
increase between 2017 and 2045 was lower than that reported by IDF. Our study predicted an increase of 26%, 
from 15.7% in 2017 to 19.8% in 2045. Differences in the T2DM levels and projections are primarily due to 
differences in the surveys used as input data—we used more (and all available) population-based survey data 
to power the modelling projections. Differences are also due to the implemented modelling methodology. To 
estimate T2DM levels, IDF used a logistic regression method rather than a dynamical population-level model 
of T2DM and its key risk factors, as is the case in the present study. Of note that the characterized T2DM epi-
demic in Jordan is similar in scale and epidemiology to the epidemics seen and characterized in other MENA 
countries, such as  Lebanon2, Saudi  Arabia2,42,  Tunisia2,43, and  Qatar2,16. However, when compared to Palestine 
and  Syria2, our estimates were somewhat larger than those estimated in the IDF report for these two countries, 
but similar to those estimated in other modelling  studies44,45. This demonstrates the largely regional nature of 
these T2DM epidemics.
Our study has limitations. The modelling predictions hinge on the representativeness of the input data, par-
ticularly the survey data. T2DM surveys in Jordan varied in study design, specific definition of outcomes, survey 
administration, and response rate, thus potentially biasing measures of T2DM and related risk factors. In most 
surveys, the non-response rate in men was substantially higher than in women (Table 1)10–15—included men 
may not have been representative of the wider population of men. For instance, physical inactivity was higher 
in men than women, contrary to expectation, especially considering that the prevalence of obesity was higher 
in  women10–15. This could be a biased result due to the sex differences in response rate. Also, body mass index 
≥ 30 kg/m2 was used to define obesity because it is a pragmatic measure in  surveys46. But this may not be the 
most representative measure to capture the impact of obesity on T2DM  incidence46. Given also the differences in 
body fat distribution between men and  women46, we may have underestimated the impact of obesity on T2DM 
among men. T2DM prevalence in men was substantially higher than in women.
Although T2DM prevalence in men was expected to be higher, the relative difference between men and 
women was larger than expected. This difference is driven by the difference observed in the actual country-
specific survey data used to calibrate the  model10–15, and seems consistent with the differences observed in other 
 countries47. Moreover, given that the T2DM surveys in Jordan varied in study design and methods and were 
conducted at different time points thus potentially introducing bias, fitting all the survey data simultaneously 
with the ordinary least-square estimator could possibly lead to overfitting that affects the results. Nonetheless, a 
regularization technique was applied to investigate overfitting and the results affirmed our findings and conclu-
sions (Supplementary Fig.S9C).
Another limitation in this study is the lack of published Jordan-specific data on the relative ratio of health-
care expenditure in T2DM individuals versus non-T2DM individuals. To be consistent with global empirical 
 evidence31, we used the conventional range of 2–3 to bracket the estimates of the T2DM economic burden. Simi-
larly, although the estimates of the RRs of T2DM with respect to the risk factors were obtained from large, quality 
prospective studies that are pooled through global systematic reviews and meta-analyses4,7,9, the representative-
ness of these RRs for the population of Jordan remains unknown. We did not formally investigate identifiability 
in this model, nor in this class of models. Unlike other disciplines, such as within host modelling and biological 
systems  modelling48–50, there is limited research on identifiability for disease population-level models, particularly 
for  diabetes51. Of note, however, that our model does not have complex non-linearities as in infectious disease 
models. Our focus also is not on parameter estimation, but on capturing the epidemiologic trends. Therefore, 
it is less likely that this class of models could be affected by serious identifiability issues. We did not explicitly 
include the waves of refugees and immigrants hosted by Jordan due to the political conflicts surrounding Jordan 
over the past few decades. Consequently, some dynamics (or sudden changes in the population) reported in 
the United Nations projections were not explicitly accounted for in the fitting of the demographic indicators.
Nonetheless, this study has several strengths. This mathematical modelling work was anchored on nationally-
representative population-based data of different surveys at different times—a total of six surveys. Model calibra-
tion ensured that a best fit of input data is attained, adjusting for discrepancies in data input and accounting for 
the level of confidence in each datapoint. This highlights the power of such modelling approach to characterize 
T2DM epidemiology. As survey outcome measures often vary due to survey quality, time, design, geographic cov-
erage, outcome definitions, selection and information biases, and differentials in response  rate52–56, this approach 
“reconciles” the differences in survey data by producing the most consistent characterization of the underlying 
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epidemiology. For example, Jordan surveys are limited by sex-differentials in response rate (Table 1)10–15. The 
model fitting, however, has adjusted for the level of confidence in each survey data by weighting each datapoint 
differentially by the response rate. Moreover, to account for potential variations or errors in each data point of 
each survey, an uncertainty analysis was conducted and the results affirmed our findings and conclusions (Sup-
plementary Fig. S9B).
Moreover, we conducted several sensitivity analyses to assess the robustness of our predictions (Supplemen-
tary Fig.S7). The analyses demonstrated that while our results are sensitive to the T2DM-obesity RR, they are 
insensitive to variations in the remaining parameters. We further conducted multivariate uncertainty analyses 
that demonstrated narrow UIs around the point estimates (Supplementary Figs. S9A and S9B). Therefore, both 
the sensitivity and uncertainty analyses affirm the robustness of our predictions.
In conclusion, Jordan is confronted with a rapidly rising T2DM epidemic over the coming decades. With 
a progressively aging population and ever-increasing obesity prevalence, T2DM incidence and prevalence will 
continue to grow despite already reaching high levels. Obesity is the driver of half of T2DM incidence, highlight-
ing the unique contribution of this risk factor to this major public health challenge. With the growing epidemic, 
T2DM health expenditure will escalate to account for a quarter of Jordan’s health expenditure. These findings 
demonstrate the criticality of mass national engagement and large-scale implementation of cost-effective preven-
tive and therapeutic interventions targeting T2DM and its risk factors.
Data availability
Data are available in the cited literature, main manuscript, and Supplementary Information. The codes pro-
grammed in MATLAB can be obtained by contacting the authors.
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